Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

被引：417

作者：

Feldmann, Marc ^{[1
]}

Maini, Ravinder N. ^{[2
]}

Woody, James N. ^{[3
]}

Holgate, Stephen T. ^{[4
]}

Winter, Gregory ^{[5
]}

Rowland, Matthew ^{[6
]}

Richards, Duncan ^{[7
]}

Hussell, Tracy ^{[8
]}

机构：

[1] Univ Oxford, Kennedy Inst Rheumatol, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Oxford OX3 7LD, England

[2] Imperial Coll London, London, England

[3] Laterell Venture Partners, San Francisco, CA USA

[4] Southampton Gen Hosp, Fac Med Clin & Expt Sci, Southampton, Hants, England

[5] Trinity Coll, Cambridge, England

[6] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford, England

[7] Botnar Res Ctr, Oxford Clin Trials Res Unit, Oxford, England

[8] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England

来源：

LANCET | 2020年 / 395卷 / 10234期

关键词：

ENDOTHELIAL GROWTH-FACTOR; TNF-ALPHA THERAPY; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; INTERLEUKIN-1; PATHOGENESIS; MULTICENTER;

D O I：

10.1016/S0140-6736(20)30858-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1407 / 1409

页数：3

共 31 条

[1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].

ABRAHAM, E ;

WUNDERINK, R ;

SILVERMAN, H ;

PERL, TM ;

NASRAWAY, S ;

LEVY, H ;

BONE, R ;

WENZEL, RP ;

BALK, R ;

ALLRED, R ;

PENNINGTON, JE ;

WHERRY, JC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941

[2]

[Anonymous], MRI ONLINE

[3]

[Anonymous], 2020, J BIOL REGUL HOMEOST

[4]

[Anonymous], 2020, NAT MICROBIOL, DOI [DOI 10.1038/s41564-020-0688-y, 10.1038/s41564-020-0688-y]

[5]

BRENNAN FM, 1989, LANCET, V2, P244

[6]

Charles P, 1999, J IMMUNOL, V163, P1521

[7] What does tumour necrosis factor excess do to the immune system long term? [J].

Clark, J ;

Vagenas, P ;

Panesar, M ;

Cope, AP .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 :70-76

[8] INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis [J].

Cohen, J ;

Carlet, J .

CRITICAL CARE MEDICINE, 1996, 24 (09) :1431-1440

[9]

DVORAK HF, 1995, AM J PATHOL, V146, P1029

[10]

European Centre for Disease Prevention and Control, 2020, COVID 19 SIT UPD WOR

← 1 2 3 4 →